-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, CanSino Biological Co.
, Ltd.
issued an announcement stating that its phase III clinical trial of recombinant new coronavirus vaccine (type 5 adenovirus vector, Ad5-nCoV, trade name: Keweisha) has made the latest progress
.
This international multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluated the effectiveness, safety, and immunogenicity of a single dose of Kevisa in adults 18 years and older
.
The results of the study showed that a single dose of Kevisa showed 57.
5% effectiveness in preventing symptomatic COVID-19 disease 28 days after vaccination and 91.
7% in preventing severe diseases; 14 days after vaccination, it was effective in preventing symptomatic COVID-19 disease.
COVID-19 disease showed 63.
7% effectiveness and 96.
0% effectiveness in preventing severe diseases
.